KR20230117574A - 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합 - Google Patents

암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합 Download PDF

Info

Publication number
KR20230117574A
KR20230117574A KR1020237018920A KR20237018920A KR20230117574A KR 20230117574 A KR20230117574 A KR 20230117574A KR 1020237018920 A KR1020237018920 A KR 1020237018920A KR 20237018920 A KR20237018920 A KR 20237018920A KR 20230117574 A KR20230117574 A KR 20230117574A
Authority
KR
South Korea
Prior art keywords
inhibitor
cancer
cdk4
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018920A
Other languages
English (en)
Korean (ko)
Inventor
피터 코넬리우스
제임스 샤나한
브래들리 제이 카버
Original Assignee
신데브알엑스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신데브알엑스, 인크. filed Critical 신데브알엑스, 인크.
Publication of KR20230117574A publication Critical patent/KR20230117574A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020237018920A 2020-11-11 2021-11-10 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합 Pending KR20230117574A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112217P 2020-11-11 2020-11-11
US63/112,217 2020-11-11
US202163166060P 2021-03-25 2021-03-25
US63/166,060 2021-03-25
PCT/US2021/058775 WO2022103834A1 (en) 2020-11-11 2021-11-10 Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20230117574A true KR20230117574A (ko) 2023-08-08

Family

ID=78821168

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018920A Pending KR20230117574A (ko) 2020-11-11 2021-11-10 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합

Country Status (8)

Country Link
US (1) US20230404963A1 (https=)
EP (1) EP4243807A1 (https=)
JP (1) JP2023550035A (https=)
KR (1) KR20230117574A (https=)
AU (1) AU2021378944A1 (https=)
CA (1) CA3198173A1 (https=)
MX (1) MX2023005501A (https=)
WO (1) WO2022103834A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CA3264343A1 (en) * 2022-08-10 2024-02-15 Syndevrx, Inc. METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20130137831A1 (en) * 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
WO2019070755A1 (en) * 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
JP2022512826A (ja) * 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用

Also Published As

Publication number Publication date
AU2021378944A1 (en) 2023-06-15
US20230404963A1 (en) 2023-12-21
MX2023005501A (es) 2023-07-27
EP4243807A1 (en) 2023-09-20
JP2023550035A (ja) 2023-11-30
WO2022103834A1 (en) 2022-05-19
CA3198173A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
JP6193268B2 (ja) Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
US12419846B2 (en) Biomarkers of METAP2 inhibitors and applications thereof
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
CA2676422A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP2019509990A (ja) チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途
KR20180042356A (ko) 암 치료 방법
JP2015044816A (ja) オキサビシクロヘプタンおよびオキサビシクロヘプテン、その調製並びに使用
TWI757720B (zh) 氧雜二環庚烷前藥
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022521081A (ja) Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
EP4469054A1 (en) Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
KR20230117574A (ko) 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합
WO2015197006A1 (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN109152750B (zh) 用于增殖性疾病的组合疗法
JP7755347B2 (ja) 腎癌の標的治療のための新規化合物及び組成物
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
TW201841888A (zh) 一種抗癌幹性之藥物
JP2024515727A (ja) チューブリン重合阻害剤としての代謝的に安定なピリミジニルジヒドロキノキサリノン
WO2021222350A1 (en) Methods of use for single molecule compounds providing multi-target inhibition to treat covid-19
WO2016119646A1 (zh) 一种舒尼替尼前药及药物组合物
CN116589464B (zh) 嘧啶并环类化合物、其制备方法和应用
KR20250033298A (ko) 아조포도필로톡신 유도체 su056의 거울상이성질체
WO2026024772A2 (en) Oxynitidine derivatives as tyrosyl dna phosphodiesterase inhibitors and radiosensitizers
WO2025001852A1 (zh) 多肽偶联物、包含所述多肽偶联物的药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241106

Comment text: Request for Examination of Application